Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

turoctocog alfa

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Factor VIIIrecombinant factor VIII N8

Narrower (1)

Novoeight

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8‐GP
Essentials Chromogenic assays may be less variable than one‐stage clot assays for measuring modified factor VIII. Chromogenic… Expand
Review
2016
Review
2016
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Background No head-to-head trials comparing recombinant factor VIII (rFVIII) products currently exist. This was a matching… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2015
Review
2015
The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A
Turoctocog alfa (NovoEight®) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients with… Expand
2015
2015
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of… Expand
Review
2015
Review
2015
Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B‐domain made from the sequence coding for 10… Expand
2014
2014
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
Haemophilia and its treatment interfere with patients' life, so health‐related quality of life (HRQoL) should be assessed when… Expand
Review
2014
Review
2014
Turoctocog Alfa for the Treatment of Hemophilia A
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor… Expand
Highly Cited
2013
Highly Cited
2013
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE